Xeris Pharmaceuticals, Inc.
3208 Red River Street
38 articles with Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced it began dosing patients in a Phase 2 clinical study to evaluate its investigational ready-to-use, fixed-ratio co-formulation of pramlintide and insulin in patients with diabetes.
The approval marks the first commercial product for Xeris.
Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE™ (glucagon) injection
Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an amended and restated loan and security agreement with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB).
In the first two weeks of September there were three scheduled PDUFA dates. One of those dates, for Celgene’s myelofibrosis drug, was approved early. Here’s a look.
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery
Xeris Pharmaceuticals, Inc. announced that is has dosed the first subject in a Phase 2 trial with its developmental ready-to-use glucagon in patients who experience hypoglycemic episodes following bariatric surgery.
Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon
Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its ready-to-use, stable liquid glucagon
6/3/2019Here’s a look at what’s on the U.S. Food and Drug Administration's calendar for the next two weeks.
Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
Data from a Phase 2 study in congenital hyperinsulinism (CHI) shared at ENDO 2019 and a budget impact model presented at AMCP reinforce the utility of Xeris’ ready-to-use, liquid-stable glucagon
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
Xeris Pharmaceuticals, Inc. announced that it has now begun dosing patients in a Phase 2 trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type 1 diabetes who experience episodes of exercise-induced hypoglycemia.
European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received Orphan Medicinal Product designation from the European Medicines Agency
Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen
Positive efficacy and utility data presented during the 18th Annual Diabetes Technology Meeting
Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen
If approved, the Xeris glucagon rescue pen would be the first ready-to-use, room-temperature stable liquid glucagon in an auto-injector to treat severe hypoglycemia
Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen
Results of two Phase 3 studies presented at the American Diabetes Association’s 78th Scientific Sessions
6/22/2018Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Xeris Pharmaceuticals secured $45 million in a Term Loan and Securities Agreement with Silicon Valley Bank and Oxford Finance, as well as closing a Series C financing with an additional $10 million.
Xeris Pharmaceuticals Achieves Phase III Milestones of its Ready-to-Use Glucagon Rescue Pen for the Treatment of Severe Hypoglycemia
Xeris has successfully completed two Phase 3 clinical studies of its investigational ready-to-use glucagon rescue pen (adult study: NCT02656069; pediatric study: NCT03091673).
Xeris also announced the publication of a Phase IIa study of a mini-dose of its read-to-use glucagon in Post-Bariatric Hypoglycemia.